BasiloBio
Abstract molecular biotech visualization
Natural Product Precision Biotech

Precision biotech for theantiviral future.

BasiloBio develops natural product-based antiviral and functional healthcare platforms for human, pet, and livestock applications.

Explore Technology View PipelineContact Us
3
Tech Platforms
9+
Milestones
1st
IBS Tech Transfer
Global
Partnerships
Trusted credentials
IBS Technology TransferPre-seed Investment CompletedFDA Facility RegistrationGreen Bio CompanyGlobal PartnershipsJeonbuk Promising Startup Scale-up 100
Company Overview

A bridge technology bio company.

BasiloBio connects promising source technologies with its own extraction, fermentation, formulation, and commercialization capabilities — building a self-sustaining bio business model.

2024
Founded
9+
Milestones
3
Tech Platforms
Global
Reach
BasiloBio research team
Milestones

A focused 24-month execution.

  1. 2024.10
    BasiloBio established
  2. 2025.02
    Core process technology patent registered
  3. 2025.04
    Vietnam probiotic sample export, approx. USD 20,000
  4. 2025.04
    Corporate R&D center established
  5. 2025.05
    Venture company certification and food registration
  6. 2025.06
    Feed manufacturing registration
  7. 2025.12
    Strategic investment from Beloved Creatures LLC
  8. 2025.12
    Selected for Jeonbuk Promising Startup Scale-up 100
  9. 2026.01
    IBS technology transfer confirmation
Unmet Need

The structural limits of conventional antiviral approaches.

Many existing antiviral strategies focus on a single viral protein or limited entry pathway. However, mutation-prone enveloped viruses can bypass single-pathway inhibition. This creates the need for a broader antiviral approach that targets common entry mechanisms.

Conventional Antivirals
  • Single target focus
  • Mutation vulnerability
  • Limited pathway coverage
BasiloBio Approach
  • Host membrane entry pathway focus
  • Dual-blocking concept
  • Broader enveloped virus potential
Core Technology Platform

Natural product precision synthesis & dual-blocking antiviral platform.

PlatyKor
Antiviral platform

PlatyKor

  • Platycodin D-derived antiviral candidate
  • Membrane fusion inhibition
  • Enveloped virus entry-blocking potential
  • IBS-origin technology transfer
Bacillus coagulans
Probiotic platform

Bacillus coagulans

  • Heat-resistant spore-forming probiotic strain
  • Fermentation and bioconversion process
  • Postbiotic and bacteriocin-related potential
  • Pet and livestock product applications
Natural Product Processing
Extraction & formulation

Natural Product Processing

  • High-purity extraction
  • Batch consistency
  • Functional ingredient standardization
  • Formulation and commercialization
Mechanism of Action

Dual-pathway blocking mechanism.

BasiloBio's platform is designed to explore antiviral mechanisms associated with membrane fusion inhibition and endosomal escape suppression.

01

Virus approaches host cell

Enveloped viruses initiate contact with the host cell membrane.

02

Membrane fusion is inhibited

The candidate is designed to interfere with membrane fusion events.

03

Endosomal escape suppressed

Endosomal escape pathways are targeted for suppression.

04

Viral replication risk reduced

Reduced viral entry lowers the potential for downstream replication.

Pipeline

A balanced pipeline across antiviral, microbiome, and functional health.

R&D
Preclinical
Commercialization
Program 01

PlatyKor Antiviral Platform

Platycodin D-derived optimized compound

Application

Enveloped virus antiviral candidate

DiscoveryPreclinicalClinicalMarket
Preclinical / Formulation
License-out / Co-development
Program 02

Bacillus coagulans Platform

Probiotic / postbiotic / bacteriocin technology

Application

Pet and livestock feed additive

DiscoveryPreclinicalClinicalMarket
Early Commercialization
Ingredient supply / B2B / Export
Program 03

Ginsenoside Rg5

High-purity Rg5 extraction & standardization

Application

Immune & antiviral functional ingredient

DiscoveryPreclinicalClinicalMarket
Preclinical Research
Functional ingredient / Licensing
Program 04

Hericium erinaceus Extract

Hericenone extraction process

Application

Functional health ingredient

DiscoveryPreclinicalClinicalMarket
R&D Pipeline
Ingredient supply / Brand partnership
Business Model

A two-track model: cash flow today, value tomorrow.

BasiloBio prioritizes early commercialization in pet and livestock applications while advancing its antiviral pipeline toward higher-value licensing opportunities.

Track 1 · Today

Early Cash Flow

Generate near-term revenue from pet & livestock products.

  • Pet care products
  • Livestock feed additives
  • Functional ingredients
  • Global raw material supply
  • B2B partnerships
Track 2 · Tomorrow

High-Value Growth

Advance antiviral candidates toward licensing and partnership.

  • Antiviral candidate development
  • GLP toxicity studies
  • IND preparation
  • Global license-out
  • Strategic pharma & animal health partnerships
Development Roadmap

From foundation to global expansion.

01
Phase 01

Platform Foundation

  • Human and livestock antiviral platform
  • Formulation optimization
  • Feed additive and spray-type development
  • Preclinical entry
  • Animal disease efficacy evaluation
  • Seed investment and TIPS preparation
02
Phase 02

Regulatory & Commercial Validation

  • GLP toxicity study
  • Livestock safety testing
  • PK/PD research
  • B2G entry preparation
  • Global livestock market partnerships
  • Series A fundraising
03
Phase 03

Global Expansion

  • IND approval and Phase 1 preparation
  • Livestock infectious disease product approval
  • Global license-out
  • Global private market expansion
  • Series B fundraising
Market Opportunity

Expanding from functional ingredients to global antiviral markets.

BasiloBio's strategy starts from near-term commercialization markets and expands toward high-value pharmaceutical and global healthcare markets.

Global API Market

Active pharmaceutical ingredient demand across regulated markets.

Global Botanical Extract Market

Growing interest in standardized natural product ingredients.

Korean Natural Feed Additive Market

Domestic livestock and pet feed channel for early revenue.

Functional Pet & Livestock Health Market

Expanding global market for animal health and wellness.

Intellectual Property & Certifications

Commercialization-ready foundation.

IBS Technology Transfer
Core Process Technology Patent
FDA Facility Registration
Corporate R&D Center
Venture Company Certification
Green Bio Company Registration
Feed Manufacturing Registration
Global Partnerships
Team

Bio research and commercialization team.

Management & Operations

To be announced
Chief Executive Officer
Expertise
Strategy · Commercialization

Leadership in bio business development and global partnerships.

To be announced
Chief Operating Officer
Expertise
Operations · Manufacturing

Oversees manufacturing, quality and supply chain.

R&D Experts

To be announced
Head of R&D
Expertise
Natural product chemistry

Leads extraction, fermentation and formulation research.

To be announced
Senior Scientist
Expertise
Antiviral biology

Focused on membrane fusion and enveloped virus research.

Research Partners & Advisors

To be announced
Scientific Advisor
Expertise
IBS-origin antiviral technology

Advisory on PlatyKor platform development.

To be announced
Industry Advisor
Expertise
Animal health · Global market

Advisory on livestock and pet health commercialization.

Contact

Partner with BasiloBio

Contact BasiloBio to discuss investment, strategic partnership, product supply, and research collaboration opportunities.

BasiloBio Co., Ltd.
Republic of Korea